Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19
Sars-CoV-2 Infection
About this trial
This is an interventional diagnostic trial for Sars-CoV-2 Infection focused on measuring SARS-CoV-2 infection, Genetic polymorphism, Polymerase Chain Reaction
Eligibility Criteria
Inclusion Criteria:
- Individuals over 18 years old
- With or without associated comorbidities: any pathology of the systems: cardiovascular, respiratory, endocrine, digestive, neurological, psychiatric, genitourinary
- Diagnosed with COVID-19 through RT-PCR (naso-oropharyngeal swab)
- Who agreed to participate in the research voluntarily
Exclusion Criteria:
- Participants who refuse to participate in the survey
- Who have lesions in the oral mucosa that make the collection of material unfeasible
- Individuals with severe xerostomia
- In cancer treatment.
Sites / Locations
- University Ninth of July
- Guarulhos City Hall
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Mild/asymptomatic cases
Serious cases
For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed mild or asymptomatic conditions.
For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed severe pathology.